Guardant Health, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Helmy Eltoukhy
- Full Time Employees
- 1,999
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- 505 Penobscot Drive Palo Alto CA United States of America 94063
- IPO Date
- Oct 4, 2018
- CIK
- 0001576280
- Website
- guardanthealth.com
- Similar Companies
- Business
- Guardant Health, Inc. is a precision oncology company specializing in blood and tissue-based diagnostic tests, real-world data sets, and AI-driven analytics to enhance cancer detection, treatment, and patient care. Founded in 2012 and headquartered in Palo Alto, California, the company provides a comprehensive portfolio of products including Guardant360 Liquid Biopsy tests (Guardant360, Guardant360 CDx, Guardant360 TissueNext, Guardant360 Response), Guardant Infinity, Guardant Reveal for early-stage cancer, the Shield test for colorectal cancer screening, and GuardantOMNI for biopharmaceutical research. It also offers integrated software solutions like Guardant Connect and research platforms such as Guardant INFORM and Guardant Galaxy. Guardant serves oncology patients, clinicians, and biopharmaceutical companies across the United States and internationally, including direct operations in Asia, the Middle East, and Africa following its full acquisition of Guardant Health AMEA which expanded its reach to 41 countries in those regions. Recent major developments include a strategic multi-year collaboration with Pfizer to leverage Guardant's liquid biopsy technology in global clinical trials and therapeutic development, including access to the Chinese market. The company has advanced its Smart Liquid Biopsy platform with expanded Medicare coverage, notably for its Guardant Reveal and Shield tests, facilitating broader adoption for cancer surveillance and screening. Guardant also completed the full acquisition of Guardant Health AMEA from SoftBank, consolidating its global operations to accelerate market penetration in high cancer burden regions. In 2024, Guardant reported record revenue growth driven by increased reimbursement and volume for Guardant360 assays, and it continues to innovate with new offerings for early detection and therapy response monitoring in multiple cancer indications. This positions Guardant Health as a leading biotechnology firm in precision oncology diagnostics and data analytics worldwide.
Here Are Tuesday’s Top Wall Street Analyst Research Calls: CoreWeave, Danaher, Hewlett Packard Enterprise, Intuit, Knight-Swift, Meta Platforms, Starwood Property Trust, Tripadvisor, and More
Guardant Health and Collaborators to Present 38 Abstracts Highlighting Breadth and Expanded Clinical Utility of Guardant Liquid Biopsy Tests Powered by InfinityAI at 2026 ASCO Annual Meeting
Guardant Health and Collaborators to Present 38 Abstracts Highlighting Breadth and Expanded Clinical Utility of Guardant Liquid Biopsy Tests Powered by InfinityAI at 2026 ASCO Annual Meeting
Guardant Health Is Poised To Break Out At The Open — Here's Why It Surged
American Cancer Society Recommends Guardant Health's Shield Blood Test in Updated Colorectal Cancer Screening Guidelines
American Cancer Society Recommends Guardant Health's Shield Blood Test in Updated Colorectal Cancer Screening Guidelines
Guardant Health Secures FDA Approval For Expanded Liquid Biopsy Test
Guardant Health Leaps On A Major Win In Cancer Detection; Will Shares Break Out?
FDA Approves New Guardant360 Liquid CDx, the Largest FDA-Approved Liquid Biopsy Panel with a 100x Expanded Footprint
FDA Approves New Guardant360 Liquid CDx, the Largest FDA-Approved Liquid Biopsy Panel with a 100x Expanded Footprint
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Guardant Health: Reveal And Shield Driving The Next Growth Phase
Guardant Health, Inc. (GH) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Guardant Health, Inc. (GH) Q1 2026 Earnings Call Transcript
Compared to Estimates, Guardant Health (GH) Q1 Earnings: A Look at Key Metrics
Guardant Health (GH) Reports Q1 Loss, Beats Revenue Estimates
Guardant Health Reports First Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
Guardant Health Receives FDA Approval for Guardant360® CDx as a Companion Diagnostic for Arvinas and Pfizer's VEPPANU (vepdegestrant) for Patients with ER+/HER2- Advanced Breast Cancer with ESR1 Mutations
Brown Advisory Sustainable Small-Cap Core Strategy Q1 2026 Portfolio Activity
Guardant Health (GH) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release